A reassessment of the Lewy body

Acta Neurologica Taiwanica

Volumn 14, Issue 2, 2005, Pages 40-47

  Au, Wing Lok ^a,b   Calne, Donald B ^a,c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b NATIONAL NEUROSCIENCE INSTITUTE   (Singapore)

^c VANCOUVER HOSPITAL AND HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Synuclein; Lewy bodies; LRRK2; PARK8; Tau

Indexed keywords

AUTOSOMAL RECESSIVE DISORDER; DEGENERATIVE DISEASE; GENE MUTATION; HUMAN; LEWY BODY; ONSET AGE; PARKINSON DISEASE; PARKINSONISM; PATHOGENESIS; REVIEW;

HUMANS; LEWY BODIES; NERVE TISSUE PROTEINS; PARKINSON DISEASE; PROTEIN-SERINE-THREONINE KINASES; SYNUCLEINS; TAU PROTEINS;

EID: 21544436041     PISSN: 10196099     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (85)

1. Gibb WR, Lees AJ. The significance of the Lewy body in the diagnosis of idiopathic Parkinson's disease. Neuropathol Appl Neurobiol 1989;15:27-44.
2. Lewy FH. Paralysis agitans: I. Pathologische anatomie. Handbuch der Neurologie III. Berlin: Springer, 1912:920-33.
3. Tretiakoff C. Contribution a l'átude de l'anatomie pathologique du locus niger et soemmering avec quelques déductions relatives á la pathogénie des troubles du tonus musculaire et de la maladie de Parkinson. University of Paris, 1919.
4. Holdorff B. Friedrich Heinrich Lewy (1885-1950) and his work. J Hist Neurosci 2002;11:19-28.
5. Braak H, Del Tredici K, Rub U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197-211.
6. Gibb WR, Scaravilli F, Michund J. Lewy bodies and subacute sclerosing panencephalitis. J Neurol Neurosurg Psychiatry 1990;53:710-1.
7. Raghavan R, Khin-Nu C, Brown A, et al. Detection of Lewy bodies in Trisomy-21 (Down's Syndrome). Can J Neurol Sci 1993;20:48-51.
8. Arawaka S, Saito Y, Murayama S, et al. Lewy body in neurodegeneration with brain iron accumulation type 1 is immunoreactive for alpha-synuclein. Neurology 1998;51: 887-9.
9. Spillantini MG. Parkinson's disease, dementia with Lewy bodies and multiple system atrophy are alpha-synucleinopathies. Parkinsonism Relat Disord 1999;5:157-62.
10. Giasson BI, Duda JE, Murray IV, et al. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 2000;290:985-9.
11. Mori H, Oda M, Komori T, et al. Lewy bodies in progressive supranuclear palsy. Acta Neuropathol (Berl) 2002;104:273-8.
12. Jellinger K. The pathology of parkinsonism. In: Marsden CD, Fahn S, eds. Movement Disorders 2. London: Butterworths, 1987:124-65.
13. Forno LS, Langston JW. Lewy bodies and aging: relation to Alzheimer's and Parkinson's diseases. Neurodegeneration 1993;2:19-24.
14. Rajput AH, Uitti RJ, Sudhakar S, et al. Parkinsonism and neurofibrillary tangle pathology in pigmented nuclei. Ann Neurol 1989;25:602-6.
15. Mizuno Y, Hattori N, Matsumine H. Neurochemical and neurogenetic correlates of Parkinson's disease. J Neurochem 1998;71:893-902.
16. Mori H, Kondo T, Yokochi M, et al. Pathologic and biochemical studies of juvenile parkinsonism linked to chromosome 6q. Neurology 1998;51:890-2.
17. Hayashi S, Wakabayashi K, Ishikawa A, et al. An autopsy case of autosomal-recessive juvenile parkinsonism with a homozygous exon 4 deletion in the parkin gene. Mov Disord 2000;15:884-8.
18. Lowe J. Lewy bodies. In: Calne DB, ed. Neurodegenerative Diseases. Philadelphia: W.B. Saunders, 1994:51-69.
19. Forno LS. Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol 1996;55:259-72.
20. Gai WP, Yuan HX, Li XQ, et al. In situ and in vitro study of colocalization and segregation of alpha-synuclein, ubiquitin, and lipids in Lewy bodies. Exp Neurol 2000;166:324-33.
21. Spillantini MG, Schmidt ML, Lee VM, et al. Alpha-synuclein in Lewy bodies. Nature 1997;388:839-40.
22. Lennox G, Lowe J, Morrell K, et al. Anti-ubiquitin immunocytochemistry is more sensitive than conventional techniques in the detection of diffuse Lewy body disease. J Neurol Neurosurg Psychiatry 1989;52:67-71.
23. van Duinen SG, Lammers GJ, Maat-Schieman ML, et al. Numerous and widespread alpha-synuclein-negative Lewy bodies in an asymptomatic patient. Acta Neuropathol (Berl) 1999;97:533-9.
24. McNaught KS, Shashidharan P, Perl DP, et al. Aggresome-related biogenesis of Lewy bodies. Eur J Neurosci 2002;16: 2136-48.
25. Lowe J, McDermott H, Landon M, et al. Ubiquitin carboxyl-terminal hydrolase (Pgp 9.5) is selectively present in ubiquitinated inclusion-bodies characteristic of human neurodegenerative diseases. J Pathol 1990;161:153-60.
26. Ii K, Ito H, Tanaka K, et al. Immunocytochemical co-localization of the proteasome in ubiquitinated structures in neurodegenerative diseases and the elderly. J Neuropathol Exp Neurol 1997;56:125-31.
27. McNaught KS, Belizaire R, Isacson O, et al. Altered proteasomal function in sporadic Parkinson's disease. Exp Neurol 2003;179:38-46.
28. Gertz HJ, Siegers A, Kuchinke J. Stability of cellsize and nucleolar size in Lewy body containing neurons of substantia-nigra in Parkinson's disease. Brain Res 1994;637:339-41.
29. Tompkins MM, Hill WD. Contribution of somal Lewy bodies to neuronal death. Brain Res 1997;775:24-9.
30. van de Warrenburg BP, Lammens M, Lucking CB, et al. Clinical and pathologic abnormalities in a family with parkinsonism and parkin gene mutations. Neurology 2001;56:555-7.
31. Sasaki S, Shirata A, Yamane K, et al. Parkin-positive autosomal recessive juvenile parkinsonism with alpha-synuclein-positive inclusions. Neurology 2004;63:678-82.
32. Abeliovich A, Schmitz Y, Farinas I, et al. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 2000;25:239-52.
33. Dauer W, Kholodilov N, Vila M, et al. Resistance of alpha-synuclein null mice to the parkinsonian neurotoxin MPTP. Proc Natl Acad Sci USA 2002;99:14524-9.
34. Drolet RE, Behrouz B, Lookingland KJ, et al. Mice lacking alpha-synuclein have an attenuated loss of striatal dopamine following prolonged chronic MPTP administration. Neurotoxicology 2004;25:761-9.
35. Masliah E, Rockenstein E, Veinbergs I, et al. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 2000;287:1265-9.
36. van der Putten H, Wiederhold KH, Probst A, et al. Neuropathology in mice expressing human alpha-synuclein. J Neurosci 2000;20:6021-9.
37. Giasson BI, Duda JE, Quinn SM, et al. Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron 2002; 34:521-33.
38. Lee MK, Stirling W, Xu Y, et al. Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 -> Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. Proc Natl Acad Sci USA 2002;99:8968-73.
39. Goldberg MS, Lansbury PT Jr. Is there a cause-and-effect relationship between alpha-synuclein fibrillization and Parkinson's disease? Nat Cell Biol 2000;2:E115-9.
40. Braak H, Sandmann-Keil D, Gai W, et al. Extensive axonal Lewy neurites in Parkinson's disease: a novel pathological feature revealed by alpha-synuclein immunocytochemistry. Neurosci Lett 1999;265:67-9.
41. Conway KA, Harper JD, Lansbury PT Jr. Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. Biochemistry 2000;39:2552-63.
42. Lee HJ, Lee SJ. Characterization of cytoplasmic alpha-synuclein aggregates. Fibril formation is tightly linked to the inclusion-forming process in cells. J Biol Chem 2002; 277:48976-83.
43. Volles MJ, Lansbury PT Jr. Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism. Biochemistry 2002;41:4595-602.
44. Volles MJ, Lansbury PT Jr. Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease. Biochemistry 2003;42:7871-8.
45. Ciechanover A, Brundin P. The ubiquitin proteasome system in neurodegenerative diseases: sometimes the chicken, sometimes the egg. Neuron 2003;40:427-46.
46. Bennett MC, Bishop JF, Leng Y, et al. Degradation of alpha-synuclein by proteasome. J Biol Chem 1999;274: 33855-8.
47. Tofaris GK, Razzaq A, Ghetti B, et al. Ubiquitination of alpha-synuclein in Lewy bodies is a pathological event not associated with impairment of proteasome function. J Biol Chem 2003;278:44405-11.
48. Kopito RR. Aggresomes, inclusion bodies and protein aggregation. Trends Cell Biol 2000;10:524-30.
49. McNaught KS, Olanow CW, Halliwell B, et al. Failure of the ubiquitin-proteasome system in Parkinson's disease. Nat Rev Neurosci 2001;2:589-94.
50. Olanow CW, Perl DP, DeMartino GN, et al. Lewy-body formation is an aggresome-related process: a hypothesis. Lancet Neurol 2004;3:496-503.
51. Le W, Appel SH. Mutant genes responsible for Parkinson's disease. Curr Opin Pharmacol 2004;4:79-84.
52. de la Fuente-Fernandez R, Calne DB. Evidence for environmental causation of Parkinson's disease. Parkinsonism Relat Disord 2002;8:235-41.
53. Hattori N, Mizuno Y. Pathogenetic mechanisms of parkin in Parkinson's disease. Lancet 2004;364:722-4.
54. Shimura H, Hattori N, Kubo S, et al. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet 2000;25:302-5.
55. Farrer M, Chan P, Chen R, et al. Lewy bodies and parkinsonism in families with parkin mutations. Ann Neurol 2001;50:293-300.
56. Itier JM, Ibanez P, Mena MA, et al. Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse. Hum Mol Genet 2003;12:2277-91.
57. Kosaka K, Yoshimura M, Ikeda K, et al. Diffuse type of Lewy body disease: progressive dementia with abundant cortical Lewy bodies and senile changes of varying degree-a new disease? Clin Neuropathol 1984;3:185-92.
58. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996;47:1113-24.
59. Aarsland D, Ballard C, Larsen JP, et al. A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson's disease with and without dementia. Int J Geriatr Psychiatry 2001;16:528-36.
60. Ballard CG, Aarsland D, McKeith I, et al. Fluctuations in attention: PD dementia vs DLB with parkinsonism. Neurology 2002;59:1714-20.
61. Gomez-Tortosa E, Newell K, Irizarry MC, et al. Clinical and quantitative pathologic correlates of dementia with Lewy bodies. Neurology 1999;53:1284-91.
62. Harding AJ, Halliday GM. Cortical Lewy body pathology in the diagnosis of dementia. Acta Neuropathol (Berl) 2001;102:355-63.
63. Colosimo C, Hughes AJ, Kilford L, et al. Lewy body cortical involvement may not always predict dementia in Parkinson's disease. J Neurol Neurosurg Psychiatry 2003; 74:852-6.
64. Hishikawa N, Hashizume Y, Yoshida M, et al. Clinical and neuropathological correlates of Lewy body disease. Acta Neuropathol (Berl) 2003;105:341-50.
65. Harding AJ, Broe GA, Halliday GM. Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain 2002;125(Pt 2):391-403.
66. Apaydin H, Ahlskog JE, Parisi JE, et al. Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response. Arch Neurol 2002;59:102-12.
67. Gibb WR, Esiri MM, Lees AJ. Clinical and pathological features of diffuse cortical Lewy body disease (Lewy body dementia). Brain 1987;110 (Pt 5):1131-53.
68. Hurtig HI, Trojanowski JQ, Galvin J, et al. Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology 2000;54:1916-21.
69. Mattila PM, Rinne JO, Helenius H, et al. Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson's disease. Acta Neuropathol (Berl) 2000;100:285-90.
70. Kovari E, Gold G, Herrmann FR, et al. Lewy body densities in the entorhinal and anterior cingulate cortex predict cognitive deficits in Parkinson's disease. Acta Neuropathol (Berl) 2003;106:83-8.
71. Churchyard A, Lees AJ. The relationship between dementia and direct involvement of the hippocampus and amygdala in Parkinson's disease. Neurology 1997;49:1570-6.
72. Braak H, Braak E, Yilmazer D, et al. Neurofibrillary tangles and neuropil threads asa cause of dementia in Parkinson's disease. J Neural Transm Suppl 1997;51:49-55.
73. Dickson DW. Tau and synuclein and their role in neuropathology. Brain Pathol 1999;9:657-61.
74. Buee L, Delacourte A. Comparative biochemistry of tau in progressive supranuclear palsy, corticobasal degeneration, FTDP-17 and Pick's disease. Brain Pathol 1999;9:681-93.
75. Schmidt ML, Martin JA, Lee VM, et al. Convergence of Lewy bodies and neurofibrillary tangles in amygdala neurons of Alzheimer's disease and Lewy body disorders. Acta Neuropathol (Berl) 1996;91:475-81.
76. Lippa CF, Schmidt ML, Lee VM, et al. Alpha-synuclein in familial Alzheimer disease: epitope mapping parallels dementia with Lewy bodies and Parkinson disease. Arch Neurol 2001;58:1817-20.
77. Duda JE, Giasson BI, Mahon ME, et al. Concurrence of alpha-synuclein and tau brain pathology in the Contursi kindred. Acta Neuropathol (Berl) 2002;104:7-11.
78. Ishizawa T, Mattila P, Davies P, et al. Colocalization of tau and alpha-synuclein epitopes in Lewy bodies. J Neuropathol Exp Neurol 2003;62:389-97.
79. Zimprich A, Biskup S, Leitner P, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004;44:601-7.
80. Wszolek ZK, Vieregge P, Uitti RJ, et al. German-Canadian family (family A) with parkinsonism, amyotrophy, and dementia - Longitudinal observations. Parkinsonism Relat Disord 1997;3:125-39.
81. Wszolek ZK, Pfeiffer RF, Tsuboi Y, et al. Autosomal dominant parkinsonism associated with variable synuclein and tau pathology. Neurology 2004;62:1619-22.
82. Zimprich A, Muller-Myhsok B, Farrer M, et al. The PARK8 locus in autosomal dominant parkinsonism: confirmation of linkage and further delineation of the disease-containing interval. Am J Hum Genet 2004;74:11-9.
83. Shen J. Protein kinases linked to the pathogenesis of Parkinson's disease. Neuron 2004;44:575-7.
84. Uitti RJ, Berry K, Yasuhara O, et al. Neurodegenerative 'overlap' syndrome: clinical and pathological features of Parkinson's disease, motor neuron disease, and Alzheimer's disease. Parkinsonism Relat Disord 1995;1:21-34.
85. Uitti RJ, Calne DB, Dickson DW, et al. Is the neuropathological 'gold standard' diagnosis dead? Implications of clinicopathological findings in an autosomal dominant neurodegenerative disorder. Parkinsonism Relat Disord 2004; 10:461-3.